New York State Teachers Retirement System Invests $5.50 Million in Elanco Animal Health Incorporated $ELAN

New York State Teachers Retirement System acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 273,261 shares of the company’s stock, valued at approximately $5,503,000. New York State Teachers Retirement System owned about 0.06% of Elanco Animal Health at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ELAN. Forum Financial Management LP raised its holdings in shares of Elanco Animal Health by 67.0% in the third quarter. Forum Financial Management LP now owns 21,839 shares of the company’s stock worth $440,000 after acquiring an additional 8,760 shares during the last quarter. Oregon Public Employees Retirement Fund purchased a new stake in Elanco Animal Health during the 3rd quarter worth about $2,014,000. State of Alaska Department of Revenue acquired a new position in Elanco Animal Health in the 3rd quarter valued at about $1,070,000. SG Americas Securities LLC lifted its holdings in Elanco Animal Health by 794.0% in the 3rd quarter. SG Americas Securities LLC now owns 127,928 shares of the company’s stock valued at $2,576,000 after purchasing an additional 113,619 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new stake in shares of Elanco Animal Health during the 3rd quarter worth about $218,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.5%

ELAN stock opened at $24.54 on Friday. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The company has a market cap of $12.19 billion, a price-to-earnings ratio of 409.07, a PEG ratio of 3.36 and a beta of 1.87. The business has a fifty day simple moving average of $22.50 and a 200-day simple moving average of $19.63. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $24.84.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction dated Friday, December 12th. The stock was acquired at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares in the company, valued at $2,806,764.90. This represents a 8.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert M. Vanhimbergen bought 6,950 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the completion of the acquisition, the chief financial officer owned 124,233 shares in the company, valued at approximately $2,688,402.12. This trade represents a 5.93% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 43,450 shares of company stock valued at $937,883. 0.89% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ELAN. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Wednesday, November 19th. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Morgan Stanley lifted their price objective on Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, December 18th. Finally, Stifel Nicolaus increased their target price on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.78.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.